Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 596 participants.
Also called NCT07047014
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 596 participants
- Registry
-
NCT07047014
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07047014. Randomized; single masking; primary purpose treatment. Start 2025-07-30 (actual); primary completion 2027-03-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke
- Acronym
- ARTS-MeVO
- Condition
- Stroke, Ischemic
- Condition
- Medium Vessel Occlusions
- Intervention (Drug)
- Tenecteplase (0.25mg/kg)
- Intervention (Drug)
- Standard medical treatment
- Lead sponsor
- Beijing Tiantan Hospital
- Collaborator
- First Affiliated Hospital of Zhejiang University
- Collaborator
- Chinese Stroke Association
Record details
- Record id
cardio:ct-nct07047014- Content hash
983dd63153150650454e7e26ee6aa345a717bed201b85be91935c377c2ffc629